ArticleBMC cancer2025
Prognostic factors and survival outcome of brain metastases in breast cancer patients: a retrospective analysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Stereotactic radiosurgery for brain metastases from male breast cancer: a multicenter retrospective study.Journal of neuro-oncology · 2026Article
- Enhanced prognostic score for breast cancer brain metastases incorporating contemporary clinical features and leptomeningeal disease: Development and validation.Breast (Edinburgh, Scotland) · 2026Article
- Factors associated with developing and surviving brain metastases in patients with breast cancer: a multi-center experience.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrain metastasis (BM) is a substantial complication in breast cancer (BC) patients. This study aimed to explore the prognostic factors and survival outcomes for patients with BM from BC.
methodsThis retrospective study included female BC patients diagnosed with BM and treated at King Fahad Medical City hospitals from May 2018 to May 2023. Univariate and multivariate Cox regression of the prognostic factors were performed to determine the predictors of overall survival (OS).
resultsA total of 136 were enrolled in the study. Twenty-six (19.4%) patients had triple negative BC, whereas 26.9% had hormone-positive BC. Regardless of the hormone status, 53.7% of the participants had HER2-positive status. Invasive lobular carcinoma (ILC) (HR = 0.067, P = 0.013), longer interval between BC diagnosis and BM occurrence (HR = 0.974, P = 0.006), brain metastasectomy (HR = 2.422, P = 0.004), and stereotactic radiotherapy (SRT) (HR = 2.326, P = 0.002) were associated with longer OS and good prognosis of BM. The time interval between BC diagnosis and BM occurrence and the histological types of BC were independent prognostic factors for survival outcomes.
conclusionAlthough BM secondary to BC is associated with poor prognosis, brain metastasectomy, SRT, longer interval between BC diagnosis and BM occurrence, and ILC status improve the survival outcomes and prognosis of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.